Homocystinuria
MONDO:0004737An autosomal recessive inherited metabolic disorder caused by mutations in the CBS, MTHFR, MTR, and MTRR genes. It is characterized by abnormalities in the methionine metabolism and is associated with deficiency of cystathionine synthase. It results in the accumulation of homocysteine in the serum. It may affect the cardiovascular, musculoskeletal and the central nervous systems.
Also known as: homocystinuria, homocystinuria (disease), CBS deficiency, cystathionine beta synthase deficiency, cystathionine synthase deficiency
12 clinical trials for this condition and its sub-types, 7 tagged with Homocystinuria itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Homocystinuria
-
Classic homocystinuria 4 trials
-
Hyperhomocysteinemia 3 trials
-
Methylmalonic aciduria and homocystinuria 1 trial · 3 incl. sub-types
6 sub-types
- Methylmalonic aciduria and homocystinuria type cblC 3 trials
- Methylmalonic aciduria and homocystinuria type cblD 2 trials
- Methylmalonic acidemia with homocystinuria, type cblJ 1 trial
- Methylmalonic aciduria and homocystinuria type cblF 1 trial
- Methylmalonic acidemia with homocystinuria, type cblX 0 trials
- Methylmalonic aciduria and homocystinuria, cb1L type 0 trials
-
Homocystinuria without methylmalonic aciduria 0 trials · 2 incl. sub-types
4 sub-types
- Methylcobalamin deficiency type cblE 2 trials
- Methylcobalamin deficiency type cblG 2 trials
- Homocystinuria-megaloblastic anemia cblD type 0 trials
- Methylcobalamin deficiency type cblDv1 0 trials
-
Can a Lab-Made enzyme tame a rare genetic disorder?
Disease control Recruiting nowThis trial tests whether pegtibatinase, a lab-made version of the CBS enzyme, can safely lower homocysteine levels in people with classical homocystinuria (HCU), a rare genetic condition that causes harmful buildup of homocysteine and methionine. The study includes children and a…
Phase 1/2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could tame rare metabolic disease
Disease control Recruiting nowThis Phase 3 trial tests pegtibatinase, an enzyme given as a shot, in 70 people aged 12–65 with classical homocystinuria. The goal is to see if it safely lowers high homocysteine levels when added to standard care. Participants receive either the drug or a placebo for 24 weeks.
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC